2025 Q4 -tulosraportti
Vain PDF
35 päivää sitten
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·13 t sittenTaken from Discord: Today, Micki, Dennis and I had an informal coffee with Jes. There were 3 of us who had shown interest in attending the general meeting. As there weren't more of us, Jes wrote to us and instead we were invited for a cup of coffee, croissants and answers to our questions. As we can somewhat see from the low cash burn in the last quarter, Cessatech operates extremely lean (~5 employees + ~15 consultants), which keeps the burn down and gives them runway all the way into 2027. Jes also mentioned that one should remember to add the upcoming tax refund of 3-4 million in Oct/Nov on top. Their loan facility of 10 million has been extended to April 2027, however, it is not something they intend to utilize. If it is utilized, it will be converted into shares at the market price. On the regulatory side, EMA has just been by for 6 days, and there is ongoing dialogue. If the timeline holds reasonably well, it looks like an approval around September. After that, individual negotiations with the countries in the EU will start, which always takes some time, but Germany could be among the first. EU revenue will probably only be truly visible in early 2027. The USA is where it starts to get interesting in the short term – launch is close, and Q2 seems most likely. The price per spray will also be higher than in the EU (which probably lies around 55 euro) so it can quickly become an important driver. They already have hospitals ready, Ventis pharma has had sales reps out and with StaQ pharma's 11 children's hospitals, it looks promising. The dental area is a possibility but not for the first 6 months after launch. Product-wise, there are two doses (small vs. larger children), both of which should be tested separately. At the same time, CT002 can progress faster because much of the work from CT001 can be reused – so there is a quite obvious pipeline effect. Brand name (Sedare) is not critical for launch, as the product is hospital-focused. All in all: We got a pretty good gut feeling. Jes seems calm and very convinced about a clear belief in the product, pipeline, and the company's long-term potential. Regards Geo
·1 päivä sitten · MuokattuI really think that approval is dragging on, the company is completely silent and there are no expectations in the market.- ·2 päivää sittenAnything new since it's rising? Or is it just a happy Easter to you all
- ·25.3.The shelf life doesn't need to be several months either. They aren't building up inventories at the hospitals. They can agree to return unused medicine. It's just a matter of getting started with the sales. What are they waiting for? No money is coming in, and the share price just keeps falling.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
35 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13 t sittenTaken from Discord: Today, Micki, Dennis and I had an informal coffee with Jes. There were 3 of us who had shown interest in attending the general meeting. As there weren't more of us, Jes wrote to us and instead we were invited for a cup of coffee, croissants and answers to our questions. As we can somewhat see from the low cash burn in the last quarter, Cessatech operates extremely lean (~5 employees + ~15 consultants), which keeps the burn down and gives them runway all the way into 2027. Jes also mentioned that one should remember to add the upcoming tax refund of 3-4 million in Oct/Nov on top. Their loan facility of 10 million has been extended to April 2027, however, it is not something they intend to utilize. If it is utilized, it will be converted into shares at the market price. On the regulatory side, EMA has just been by for 6 days, and there is ongoing dialogue. If the timeline holds reasonably well, it looks like an approval around September. After that, individual negotiations with the countries in the EU will start, which always takes some time, but Germany could be among the first. EU revenue will probably only be truly visible in early 2027. The USA is where it starts to get interesting in the short term – launch is close, and Q2 seems most likely. The price per spray will also be higher than in the EU (which probably lies around 55 euro) so it can quickly become an important driver. They already have hospitals ready, Ventis pharma has had sales reps out and with StaQ pharma's 11 children's hospitals, it looks promising. The dental area is a possibility but not for the first 6 months after launch. Product-wise, there are two doses (small vs. larger children), both of which should be tested separately. At the same time, CT002 can progress faster because much of the work from CT001 can be reused – so there is a quite obvious pipeline effect. Brand name (Sedare) is not critical for launch, as the product is hospital-focused. All in all: We got a pretty good gut feeling. Jes seems calm and very convinced about a clear belief in the product, pipeline, and the company's long-term potential. Regards Geo
- ·1 päivä sitten · MuokattuI really think that approval is dragging on, the company is completely silent and there are no expectations in the market.
- ·2 päivää sittenAnything new since it's rising? Or is it just a happy Easter to you all
- ·25.3.The shelf life doesn't need to be several months either. They aren't building up inventories at the hospitals. They can agree to return unused medicine. It's just a matter of getting started with the sales. What are they waiting for? No money is coming in, and the share price just keeps falling.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
35 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13 t sittenTaken from Discord: Today, Micki, Dennis and I had an informal coffee with Jes. There were 3 of us who had shown interest in attending the general meeting. As there weren't more of us, Jes wrote to us and instead we were invited for a cup of coffee, croissants and answers to our questions. As we can somewhat see from the low cash burn in the last quarter, Cessatech operates extremely lean (~5 employees + ~15 consultants), which keeps the burn down and gives them runway all the way into 2027. Jes also mentioned that one should remember to add the upcoming tax refund of 3-4 million in Oct/Nov on top. Their loan facility of 10 million has been extended to April 2027, however, it is not something they intend to utilize. If it is utilized, it will be converted into shares at the market price. On the regulatory side, EMA has just been by for 6 days, and there is ongoing dialogue. If the timeline holds reasonably well, it looks like an approval around September. After that, individual negotiations with the countries in the EU will start, which always takes some time, but Germany could be among the first. EU revenue will probably only be truly visible in early 2027. The USA is where it starts to get interesting in the short term – launch is close, and Q2 seems most likely. The price per spray will also be higher than in the EU (which probably lies around 55 euro) so it can quickly become an important driver. They already have hospitals ready, Ventis pharma has had sales reps out and with StaQ pharma's 11 children's hospitals, it looks promising. The dental area is a possibility but not for the first 6 months after launch. Product-wise, there are two doses (small vs. larger children), both of which should be tested separately. At the same time, CT002 can progress faster because much of the work from CT001 can be reused – so there is a quite obvious pipeline effect. Brand name (Sedare) is not critical for launch, as the product is hospital-focused. All in all: We got a pretty good gut feeling. Jes seems calm and very convinced about a clear belief in the product, pipeline, and the company's long-term potential. Regards Geo
- ·1 päivä sitten · MuokattuI really think that approval is dragging on, the company is completely silent and there are no expectations in the market.
- ·2 päivää sittenAnything new since it's rising? Or is it just a happy Easter to you all
- ·25.3.The shelf life doesn't need to be several months either. They aren't building up inventories at the hospitals. They can agree to return unused medicine. It's just a matter of getting started with the sales. What are they waiting for? No money is coming in, and the share price just keeps falling.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt